Irbesartan Tolife (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands and the kidney. This prevents angiotensin II‑mediated vasoconstriction and aldosterone release, resulting in vessel relaxation, reduced sodium and water retention, lower blood pressure, and decreased pressure within the glomeruli of the kidneys.

The dose of Irbesartan Tolife is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, kidney function, and overall health status. The prescriber determines the appropriate strength, frequency and any titration schedule, following local prescribing guidelines.

Irbesartan is generally not recommended during pregnancy, especially in the second and third trimesters, because it may affect fetal kidney development. Limited data are available for breastfeeding; therefore, a health‑care professional should be consulted before use in nursing mothers.

To order Irbesartan Tolife, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to irbesartan is the ACE‑inhibitor class (e.g., enalapril, lisinopril). Both lower blood pressure by interfering with the renin‑angiotensin system, but ARBs like irbesartan are less likely to cause cough and angioedema. Choice depends on patient tolerance, comorbidities and physician preference.

Irbesartan Tolife tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Irbesartan Tolife is taken orally, usually once daily, with a glass of water. It can be taken with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the tablet should be swallowed whole or split.

Serious risks include hyperkalemia (high blood potassium), angioedema (swelling of the face, lips, tongue or airway), and acute kidney injury. Patients should report symptoms such as unusual swelling, muscle weakness, or a sudden drop in urine output to their health‑care provider promptly.

Irbesartan Tolife should be avoided in individuals with known hypersensitivity to irbesartan or any component of the formulation, in patients with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for those with severe renal impairment or uncontrolled hyperkalemia.